Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NIROGACESTAT HYDROBROMIDE vs NIRSEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

NIROGACESTAT HYDROBROMIDE vs NIRSEVIMAB: Safety Overview

Metric	NIROGACESTAT HYDROBROMIDE	NIRSEVIMAB
Total FAERS Reports	166	247
Deaths Reported	0	5
Death Rate	N/A	2.0%
Hospitalizations	18	149
Average Patient Age	46.8 yrs	0.3 yrs
% Female Patients	63.0%	42.3%
FDA Approval Date	Apr 4, 2024	N/A
Manufacturer	N/A	Sanofi Pasteur Inc.
Route	N/A	INTRAMUSCULAR
Marketing Status	Prescription	N/A